Oral CR845: Phase I data

Top-line data from a double-blind, placebo-controlled, U.S. Phase Ia/Ib trial in 150 healthy volunteers showed that single doses of 0.1-10 mg oral CR845 and twice-daily doses of 0.1, 1 and 5 mg oral C...